Dianthus Therapeutics, Inc. $DNTH Shares Bought by Polar Capital Holdings Plc

Polar Capital Holdings Plc grew its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 34.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,004,728 shares of the company’s stock after buying an additional 256,725 shares during the period. Polar Capital Holdings Plc’s holdings in Dianthus Therapeutics were worth $41,405,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Fairmount Funds Management LLC lifted its stake in Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after purchasing an additional 600,000 shares during the last quarter. Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC lifted its position in shares of Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after buying an additional 175,000 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DNTH has been the subject of several research reports. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Truist Financial raised their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Oppenheimer lifted their target price on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $78.88 on Wednesday. Dianthus Therapeutics, Inc. has a one year low of $16.64 and a one year high of $96.50. The company has a 50-day simple moving average of $86.88 and a 200-day simple moving average of $65.73. The firm has a market capitalization of $4.31 billion, a P/E ratio of -19.10 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Ryan Savitz sold 8,224 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the sale, the executive vice president owned 8,224 shares of the company’s stock, valued at approximately $738,844.16. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 149,121 shares of company stock worth $12,635,454. Corporate insiders own 3.02% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.